Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
February 12, 2015
Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
January 12, 2015
Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015
January 8, 2015
Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study
January 5, 2015
Revance Therapeutics Announces Initiation of BELMONT Phase 2 Active Comparator Trial of Injectable RT002
December 18, 2014
Revance Therapeutics Added to NASDAQ Biotechnology Index
November 20, 2014
Revance Therapeutics, Inc. Announces Participation in 26th Annual Piper Jaffray Healthcare Conference
November 12, 2014
Revance Therapeutics Releases Third Quarter 2014 Results
November 4, 2014
Revance Therapeutics, Inc. Announces Participation in Credit Suisse 2014 Healthcare Conference
October 29, 2014
Revance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014
October 1, 2014
Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow's Feet Lines
Displaying 241 - 250 of 280